Himachal Pradesh high court restrains DRL from selling BI’s diabetic drug Jardiance

Dr Reddy’s on Thursday said Himachal Pradesh high court has issued an interim injunction restraining them from manufacturing and selling generic version of German drug maker Boehringer Ingelheim‘s (BI) diabetes drug Jardiance.

The drugmaker said it is reviewing legal options including filing an appeal against the court order.

Dr Reddy’s has launched copies of Jardiance (empagliflozin), which has valid patent in India until 2025. BI has sought restraining order on manufacture and sale of the drug.

Jardiance is top-selling drug for BI in India.

  • Related Posts

    Gaudium IVF launches AI powered Signature Labs; kicks off 19 centre expansion

    Gaudium IVF and Women Health Limited, India’s first publicly listed IVF chain, kicked off its first milestone in the company’s planned 19-centre expansion, as outlined in the growth roadmap shared…

    WHO releases updated guidelines on reducing the risk of cognitive decline and dementia

    The World Health Organization (WHO) released updated guidelines on reducing the risk of cognitive decline and dementia, providing countries with evidence-based recommendations to help prevent or delay the onset of…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Gaudium IVF launches AI powered Signature Labs; kicks off 19 centre expansion

    Gaudium IVF launches AI powered Signature Labs; kicks off 19 centre expansion

    WHO releases updated guidelines on reducing the risk of cognitive decline and dementia

    WHO releases updated guidelines on reducing the risk of cognitive decline and dementia

    Kerala researchers develop biosensor to measure snake venom for faster treatment

    Kerala researchers develop biosensor to measure snake venom for faster treatment

    Hyderabad pharma firm executives donate ₹2 crore to TTD scheme in Tirumala

    Hyderabad pharma firm executives donate ₹2 crore to TTD scheme in Tirumala

    Pharma pricing policy threatens innovation

    Pharma pricing policy threatens innovation

    16 empanelled hospitals face action after negligence in Ayushman Scheme

    16 empanelled hospitals face action after negligence in Ayushman Scheme